Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
32,500
Employees32,500
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
32,500
Employees32,500

BMY Key Statistics

Market cap
114.21B
Market cap114.21B
Price-Earnings ratio
15.70
Price-Earnings ratio15.70
Dividend yield
4.47%
Dividend yield4.47%
Average volume
10.85M
Average volume10.85M
High today
High today
Low today
Low today
Open price
$56.62
Open price$56.62
Volume
0.00
Volume0.00
52 Week high
$62.89
52 Week high$62.89
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

With a market cap of 114.21B, Bristol-Myers Squibb(BMY) trades at $55.90. The stock has a price-to-earnings ratio of 15.70 and currently yields dividends of 4.47%.

Bristol-Myers Squibb(BMY) stock opened on 2026-06-17 at $56.62. The price climbed to — and dipped to —.

The Bristol-Myers Squibb(BMY)'s current trading volume is 0, compared to an average daily volume of 10.85M.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $62.89 at its peak.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $62.89 at its peak.

BMY News

TipRanks 19h
Bristol-Myers Squibb’s Real World Kidney Cancer Study Signals Durable Immunotherapy Momentum

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks...

Investor's Business Daily 21h
Biotech Whips Violently Between Red And Green — What's Going On? - Investor's Business Daily

...

Biotech Whips Violently Between Red And Green — What's Going On? - Investor's Business Daily
Simply Wall St 1d
Bristol Myers Squibb Stock Could Be 10.7% Undervalued After Kidney Cancer Trial Expansion

Bristol-Myers Squibb (BMY) stock is back in focus after the company expanded its kidney cancer trial through a clinical collaboration with Arcus Biosciences, ad...

Bristol Myers Squibb Stock Could Be 10.7% Undervalued After Kidney Cancer Trial Expansion

Analyst ratings

61%

of 31 ratings
Buy
35.5%
Hold
61.3%
Sell
3.2%

More BMY News

TipRanks 5d
Bristol-Myers Squibb Advances Phase 1 Liver Study for New Drug BMS-986435

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb is running a new early-stage trial to test how its...

TipRanks 5d
Bristol-Myers Squibb’s Mavacamten Study Signals Real‑World Momentum in Heart Drug Market

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb has completed a real-world study titled “Patient C...

Simply Wall St 7d
Camzyos Priority Review And New Oncology Data Could Be A Game Changer For Bristol-Myers Squibb

In recent weeks, Arcus Biosciences announced a clinical trial collaboration with Bristol Myers Squibb to add its HIF-2a inhibitor casdatifan to the BMS-sponsore...

Camzyos Priority Review And New Oncology Data Could Be A Game Changer For Bristol-Myers Squibb

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.